The latest announcement is out from Oruka Therapeutics ( ($ORKA) ). Oruka Therapeutics, Inc. has updated the employment agreements for CEO Lawrence Klein and Senior VP of Finance Arjun Agarwal,
The latest announcement is out from Oruka Therapeutics ( ($ORKA) ). Oruka Therapeutics, Inc. has updated the employment agreements for CEO Lawrence Klein and Senior VP of Finance Arjun Agarwal,
Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on September 25. David Risinger has given his Buy rating due to a
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating yesterday. Sam Slutsky has given his Buy rating due to a combination of
Oruka Therapeutics announced new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, from its presentation at the European Academy of Dermatology and Venereology Congress. ORKA-001 has
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration